Unison is the leading provider of home ownership investments, modernizing home financing through long-term partnerships. Unison works with lenders, regulators and institutional investors to integrate home ownership investing into the U.S. housing finance system. Unison HomeBuyer helps purchasers buy the home they want with less debt and risk, typically by doubling the down payment. The larger down payment makes it easier to qualify for a loan, increases buying power, lowers the monthly payment and/or allows a buyer to reserve cash. Unison HomeOwner provides current homeowners with cash to eliminate debt, remodel, pay for school, invest or use as a cash cushion, without the added debt or payments of a home equity loan or HELOC.
Region: North America
Benchling
Benchling is the industry-leading software platform for life science R&D. Purpose-built for biologics, Benchling combines an Electronic Lab Notebook (ELN), Laboratory Information Management System (LIMS), and a molecular biology design suite into a single, unified, cloud-based platform. It’s trusted by over 200,000 scientists — from pioneering academics and high-growth startups to all of the world’s top 50 biopharma companies.
Farapulse
Farapulse is a medical device company developing a novel approach to treating a range of arrhythmias using pulsed electric field. Farapulse was acquired by Boston Scientific in 2021.
Beam Therapeutics
Beam Therapeutics (NASDAQ: BEAM) is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time.
Papaya Payments
Papaya Payments is a free and easy way to pay your bills. Just snap a photo of a paper bill and Papaya will automatically validate it and facilitate your payment.
Tempest Therapeutics
Tempest Therapeutics (Nasdaq: TPST) is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.
NFlection Therapeutics
NFlection Therapeutics is a biopharmaceutical company focused on the development of therapies for Neurofibromatosis 1 (NF1), and other disorders.
Indalo Therapeutics
Indalo Therapeutics, a preclinical biotechnology company dedicated to developing therapies for fibrosis, is formed with an experienced team, strong IP, and robust portfolio of drug candidates.
Avalyn Pharmaceuticals
Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, at the level of C3, the central protein in the complement cascade. Acquired by Biogen in 2026.